INTRODUCTION
Skeletal muscle is composed of a heterogeneous population of muscle fibers that display several distinct properties (Schiaffino and Reggiani, 2011) . Type I (slow twitch) muscle fibers utilize oxidative metabolism, are rich in mitochondria, display increased vascularization, and are fatigue resistant. Type II (fast twitch) fibers utilize glycolytic metabolism and fatigue rapidly (Schiaffino and Reggiani, 2011) . Adult skeletal muscle can undergo conversion between these fiber types in response to exercise training or the pattern of motor neuron activity (Pette, 1998) .
The basic helix-loop-helix (bHLH) transcription factor MyoD possesses the remarkable ability to convert most cell types into multinucleated, contractile myotubes through forced expression in cell culture and functions as an essential regulator of myogenesis (Tapscott, 2005) . MyoD is also reutilized for multiple distinct roles in postnatal muscle, including fiber type control (Legerlotz and Smith, 2008) . MyoD is expressed more highly in fast fibers than in slow fibers, and Myod1-null mice show shifts in fiber type of fast muscle toward a slower phenotype (Hughes et al., 1997; Macharia et al., 2010) . Conversely, overexpression of an active form of MyoD in muscle results in a slow-to-fast fiber type conversion (Ekmark et al., 2007) . MyoD binds DNA as a heterodimer with members of the E-protein family of bHLH proteins through the interaction of the HLH domains (Tapscott, 2005) . The N terminus of MyoD encodes an activation domain that also contains a motif referred to as the C/H domain, which has been proposed to confer ''pioneer'' activity to MyoD through interactions with the histone acetyltransferase p300/CBP and other chromatin remodeling enzymes (Berkes and Tapscott, 2005; Tapscott, 2005) .
Nuclear factor of activated T cell (NFAT) proteins comprise a family of five transcription factors (NFATc1, NFATc2, NFATc3, NFATc4, and NFAT5) that are regulated by the phosphatase calcineurin (Hogan et al., 2003) . Calcineurin signaling plays a key role in the maintenance of the slow fiber phenotype in adult muscle (Hogan et al., 2003) . NFAT proteins are known to regulate slow fiber genes in cell culture systems (Chin et al., 1998; Wu et al., 2000) , but a role for NFAT proteins in control of fiber type in vivo has not yet been established. Although NFATc1 is the predominant NFAT isoform expressed in adult skeletal muscle (Rana et al., 2008) , studies interrogating its role in muscle in vivo have been limited because nfatc1-null mice die at embryonic day 12.5 due to cardiac valve defects (Hogan et al., 2003) .
Here, we inactivated nfatc1 exclusively in skeletal muscle. We demonstrate that NFATc1 is required in vivo for the proper balance of slow type I and fast type II fibers and for fast-to-slow fiber switching in response to exercise. Unexpectedly, we found that NFATc1 inhibits expression of MyoD-dependent fast fiber genes in a DNA-binding independent fashion. NFATc1 inhibits MyoD function by physically interacting with and blocking the essential interaction of the MyoD N-terminal activation domain with p300 and subsequent activation of MyoD target genes. These studies demonstrate that NFATc1 is an essential regulator of fiber typespecific gene expression and fiber type switching in response to exercise and establish NFATc1 as a negative regulator of MyoD.
RESULTS

MyoD Function Is Negatively Regulated by NFATc1
The Mef2c gene is a direct transcriptional target of MyoD via a skeletal-muscle-specific promoter (Dodou et al., 2003; Wang et al., 2001) . To gain additional insight into the regulation of Mef2c in skeletal muscle, we analyzed its promoter for conserved transcription factor binding sites. In addition to the previously described MyoD binding sites (E boxes), we also identified five consensus NFAT binding sites ( Figure S1 ). Therefore, we examined the effect of several NFAT proteins on Mef2c promoter activity in the presence and absence of MyoD (Figure 1A) . NFATc1, NFATc3, and NFATc4 alone had no effect on the Mef2c promoter, whereas MyoD strongly transactivated the Mef2c reporter plasmid ( Figure 1A) . Strikingly, MyoD-dependent transactivation was strongly repressed by NFATc1, but not by NFATc3 or NFATc4 ( Figure 1A ; data not shown), suggesting a role specifically for NFATc1 in the inhibition of MyoD transactivation.
To determine if NFATc1 repressed the Mef2c promoter through the NFAT sites, we generated a Mef2c reporter construct encompassing the MyoD-dependent E boxes but lacking all of the NFATc1-binding sites ( Figure S1 , nucleotides shown in red). This reporter was strongly transactivated when cotransfected with MyoD, and surprisingly, MyoD-dependent activation of the reporter was still profoundly reduced when an NFATc1 expression plasmid was also cotransfected ( Figure 1B ). These results demonstrate that NFATc1 inhibition of MyoD activity does not require the NFAT cis-regulatory elements and suggest that it may occur through DNA-independent interaction with MyoD.
To further investigate the inhibition of MyoD-dependent transactivation by NFATc1, we examined the activation of two other established MyoD-dependent target promoters from the myogenin and mrf4 genes (Black et al., 1995; Edmondson et al., 1992) in the presence or absence of NFATc1 ( Figures 1C  and 1D ). Importantly, MyoD strongly transactivated each of these other reporters, and this transactivation was repressed by NFATc1, but not by NFATc3 ( Figures 1C and 1D) .
We next examined whether NFATc1 influenced MyoD-mediated myogenic conversion ( Figures 1E-1I ). Control transfected C3H10T1/2 cells did not express myosin heavy chain (MyHC) nor did they form multinucleated myotubes ( Figure 1E ). Similarly, transfection of an NFATc1 expression vector alone did not result in myotube formation or MyHC expression ( Figure 1F ). As expected, transfection of a MyoD expression vector resulted in robust myogenic conversion as shown by the formation of MyHC-positive myotubes ( Figure 1G ). Coexpression of NFATc1 with MyoD resulted in a nearly complete inhibition of myotube formation and myosin heavy chain expression ( Figure 1H ). Western blot analyses of fast MyHC ( Figure 1I ) showed nearly identical results: control and NFATc1 transfected C3H10T1/2 cells had no expression of MyHC ( Figure 1I ) whereas MyoD induced robust MyHC expression ( Figure 1I , lane 3), and this induction was profoundly inhibited by coexpression of NFATc1 ( Figure 1I , lane 4).
Generation of a Skeletal-Muscle-Specific Knockout of nfatc1 Although NFATc1 expression in skeletal muscle is well established (Hogan et al., 2003) , we confirmed NFATc1 expression in the nuclei of both slow and fast myofibers, and we found that NFATc1 and MyoD were coexpressed in skeletal muscle ( Figure S2) . Therefore, to test the role of NFATc1 in the regulation of MyoD-dependent genes in vivo and to determine the function of NFATc1 in skeletal muscle, we generated mice with nfatc1 loss of function in skeletal muscle (Figure 2A ). Skeletal-musclespecific nfatc1 knockout mice (nfatc1 SkMKO ) were born at Mendelian frequency ( Figure S3A ) and survived to adulthood with no overt phenotype (data not shown). We observed greater than 80% reduction in nfatc1 mRNA levels in the muscles of nfatc1 SkMKO mice compared to nfatc1 flox/+ (control) mice by quantitative PCR (qPCR) and western blot analyses ( Figures  S3B and S3C ). We did not observe any significant differences in growth, body mass, or muscle weight between control and nfatc1 SkMKO mice ( Figures S3D and S3E ).
Expression of MyoD-Dependent Genes Is Increased in the Absence of NFATc1 In Vivo
The observation that NFATc1 strongly repressed MyoD-dependent activation of the Mef2c, myogenin, and mrf4 promoters ( Figure 1 ) prompted us to examine expression of the endogenous genes in nfatc1 SkMKO and control mice ( Figure 2B ).
Importantly, expression of Mef2c, mrf4, and myogenin was significantly increased in the absence of NFATc1 in vivo (Figure 2B ). Other known MyoD target genes, including desmin, nestin, muscle creatine kinase, and the Myod1 gene itself, also showed significantly increased expression in the skeletal muscle of nfatc1 SkMKO mice compared to controls ( Figure 2B ). These data support the idea that NFATc1 represses MyoD-dependent gene activation in vivo.
NFATc1 Controls Skeletal Muscle Fiber Type Composition and Switching in Response to Exercise
Given the role of calcineurin-NFAT signaling in skeletal muscle fiber type regulation based on studies performed in cell culture model systems (Chin et al., 1998; Wu et al., 2000) , we reasoned that mice lacking NFATc1 in skeletal muscle might have altered fiber type composition. To test this hypothesis, we used metachromatic ATPase staining to label slow and fast fibers in the soleus and found that nfatc1 SkMKO mice had a lower percentage of slow fibers than control mice (Figures 2C and 2E; 34 .5% versus 44.5%; p = 0.006). These findings support a role for NFATc1 in establishing or maintaining the slow fiber phenotype and provide genetic evidence for NFATc1 in the regulation of fiber type composition in vivo.
The conversion of fast fibers to slow fibers can be induced in mice in response to a continuous period of voluntary exercise (Pette, 1998) . The mouse soleus muscle contains a significant percentage of slow fibers under normal conditions and is extensively studied as a model for understanding signals involved in fiber type regulation. Therefore, we examined the fiber type composition of the soleus muscle following a 7-day period of voluntary exercise. Control mice showed a significant increase in the percentage of slow fibers in response to exercise ( SkMKO mice compared to controls was also observed by western blot ( Figure 2G ). Interestingly, we did not observe significant changes in slow fiber gene expression at the transcript level ( Figure 2F , dark blue bars), even though we observed a significant reduction in the percentage of slow fibers in nfatc1 SkMKO muscles ( Figures 2C and 2E ) and in the amount of slow myosin by western blot ( Figure 2G ). The observation that slow myosin protein expression decreased whereas mRNA was not significantly changed suggests that posttranscriptional mechanisms may be involved in maintaining the appropriate myosin expression in muscle. Our observations also suggest the possibility that NFATc1 might function in skeletal muscle fiber type control by repressing expression of MyoD-dependent fast muscle genes.
NFATc1 Physically Interacts with MyoD
To gain further insight into the repression of MyoD activity by NFATc1, we tested whether NFATc1 physically interacts with MyoD ( Figure 3 ). NFATc1 was efficiently coimmunoprecipitated by anti-MyoD in cells expressing MyoD, but not in control transfected cells ( Figure 3A) . We found that the DNA-binding domain (DBD) of NFATc1 (REL domain) was necessary and sufficient for the physical interaction with MyoD ( Figure 3B ). Similarly, we examined the interaction of various domains of MyoD with NFATc1 ( Figures 3C-3E ). MyoD truncations that contained the N terminus and bHLH region but lacked the C terminus (DC) were efficiently immunoprecipitated by anti-NFATc1 ( Figure 3C ). In contrast, MyoD truncations lacking the N terminus (DN) failed to interact with NFATc1 ( Figure 3D ), suggesting that the MyoD N terminus was required for interaction with NFATc1. Consistent with this notion, we found that the MyoD N-terminal activation domain alone (MyoD 1-101) was coimmunoprecipitated by anti-NFATc1 ( Figure 3E ). These experiments demonstrate that the MyoD N terminus is necessary and sufficient for interaction with NFATc1.
NFATc1 Inhibits MyoD Transactivation
We considered several possible MyoD functions that might be inhibited by NFATc1. Notably, MyoD nuclear localization was unaffected by coexpression with either wild-type or a constitutively active form of NFATc1 ( Figure S4 ). Likewise, NFATc1 did not affect MyoD-E12 DNA binding in an in vitro electrophoretic mobility shift assay (EMSA), which also suggested that MyoD-E12 dimerization was unlikely to be affected by NFATc1 because dimerization is prerequisite to efficient DNA binding in EMSA ( Figure S5) .
As an additional test of the effect of NFATc1 on MyoD-E protein function, we employed a modified mammalian two-hybrid assay in which the E12 bHLH domain (lacking a transactivation domain) was fused to the GAL4 DBD and was used as bait for recruitment and activation by full-length MyoD ( Figure 4A , model). Coexpression of MyoD with GAL4-E12 bHLH resulted in robust activation of the GAL4-dependent upstream activating sequence (UAS) reporter due to MyoD-E12 bHLH dimerization and activation by MyoD ( Figure 4A ). NFATc1 coexpression potently inhibited the effect of MyoD on the reporter ( Figure 4A , compare lanes 6 and 7), whereas NFATc3 had no effect (Figure 4A, lane 8) . We also used GAL4-MyoD bHLH as bait and the E protein bHLH domain fused to the VP16 activation domain as prey (Figure 4B , model). GAL4-MyoD bHLH lacks a transactivation domain and therefore had no effect on reporter activation on its own, but coexpression of E12-VP16 resulted in potent activation ( Figure 4B ). Importantly, coexpression of NFATc1 had no effect on activation by E12-VP16 ( Figure 4B , compare lanes 6 and 7), suggesting that NFATc1 does not inhibit MyoD-E protein dimerization. Taken together, the results in Figures 4A and 4B support the idea that NFATc1 inhibits transactivation by MyoD.
As an explicit test of the effect of NFATc1 on MyoD-mediated transactivation, full-length MyoD was fused directly to the GAL4 DBD and activation of a UAS-dependent reporter was examined ( Figure 4C, model) . MyoD was sufficient to activate the reporter more than 10-fold, and coexpression of NFATc1 significantly inhibited activation of the reporter ( Figure 4C, compare lanes 3  and 4) . Importantly, the MyoD N terminus, which encodes the major transactivation domain of MyoD (Berkes and Tapscott, 2005; Tapscott, 2005) , was also sufficient to activate the reporter when fused to the GAL4 DBD, and NFATc1 coexpression significantly inhibited that activation ( Figure 4C , compare lanes 5 and 6). This observation, combined with the observation that NFATc1 specifically interacted with the N terminus of MyoD (Figure 3 ), suggests that a direct protein-protein inhibitory interaction accounts for the mechanism underlying NFATc1-mediated inhibition of MyoD transactivation.
NFATc1 Disrupts MyoD Interaction with p300
The N terminus of MyoD interacts with the histone acetyltransferase p300, and that interaction is essential for MyoD-mediated conversion of fibroblasts into myotubes (Puri et al., 1997; Sartorelli et al., 1997 ). Therefore, we tested the hypothesis that NFATc1 might inhibit MyoD-p300 interaction ( Figure 5A ). Cotransfection of MyoD and p300 resulted in efficient coimmunoprecipitation of MyoD with anti-p300 ( Figure 5A , lane 4, red asterisk). Importantly, coexpression of NFATc1 inhibited p300-MyoD interaction ( Figure 5A , lane 7, red asterisk). The inhibition of MyoD-p300 interaction by NFATc1 suggested the possibility that NFATc1 might be blocking recruitment of p300 to MyoD-dependent target genes in vivo. To test this idea, we examined p300 occupancy at MyoD-dependent targets, fast fiber genes, and slow fiber genes from wild-type and nfatc1
SkMKO soleus muscles ( Figure 5B ). Strikingly, p300 occupancy at the Mef2c, myogenin, and mrf4 promoters was higher in nfatc1 SkMKO mice than in controls ( Figure 5B ). In addition, p300 occupancy was higher at fast fiber genes in the absence of NFATc1 but was unchanged at slow fiber genes ( Figure 5B ). These data support a role for NFATc1 in blocking MyoD recruitment of p300 in vivo.
Previous studies have suggested that p300 is rate limiting for MyoD-mediated conversion of fibroblasts to myotubes (Sartorelli et al., 1997) . Therefore, we predicted that addition of excess p300 might be sufficient to rescue the NFATc1-mediated inhibition of MyoD. In the absence of p300, NFATc1 nearly completely inhibited MyoD-mediated conversion of C3H10T1/2 cells into myotubes ( Figures 5C and 5C 0 ). Remarkably, addition of p300 in the presence of MyoD and NFATc1 partially overcame the NFATc1-mediated inhibition of MyoD conversion (Figures 5D 0 and 5E 0 ). Quantification of the MyoD conversion in the presence and absence of excess p300 showed that statistically significant rescue of NFATc1 inhibition of MyoD occurred in a dose-dependent fashion ( Figure 5F ). Together, these data strongly support the notion that NFATc1 inhibits MyoD by disrupting interaction of p300 with the MyoD N-terminal transcriptional activation domain.
DISCUSSION
Regulation of Skeletal Muscle Fiber Type by NFATc1
Inhibition of MyoD NFAT proteins are major effectors of calcineurin signaling, and calcineurin-dependent transcriptional pathways are involved in the control of skeletal muscle fiber type (Chin et al., 1998; Naya et al., 2000; Parsons et al., 2003 Parsons et al., , 2004 . Several prior studies have supported a role for the NFAT family in the activation of slow fiber genes and concomitant repression of fast fiber genes in cell-culture-based studies and through gain-of-function in vivo muscle electroporation studies (Calabria et al., 2009; McCullagh et al., 2004; Rana et al., 2008) . Interestingly, delivery of a slow pattern of electrical activity mimicking endurance exercise to fast muscle fibers causes fast-to-slow fiber type switching (Pette, 1998; Schiaffino and Reggiani, 2011) and also results in the inactivation of MyoD (Ekmark et al., 2007) . Given the opposing functions of MyoD and NFAT in the control of fast versus slow fiber gene expression in response to electrical stimulation (Calabria et al., 2009; Ekmark et al., 2007; McCullagh et al., 2004) and our findings that NFATc1 potently represses MyoD function, we hypothesize that NFATc1 promotes the slow fiber phenotype in part through repression of MyoD activity. Interestingly, all myogenic bHLH proteins contain an N-terminal activation domain but differ in whether or not they contain an N-terminal C/H domain (Berkes and Tapscott, 2005; (MyoD(N) ) to the GAL4 DBD resulted in potent activation of the UAS reporter due to the strong activation domains of MyoD. Coexpression of NFATc1 significantly inhibited the MyoD activation domain (compare lanes 3 and 4 and lanes 5 and 6). Results in all panels are reported as the mean fold activation plus SEM from four independent transfections. Models depicting the mammalian two-hybrid (A and B) and onehybrid (C) assays are shown to the right of their respective graphs. See also Figures S4 and S5 . Tapscott, 2005) . Thus, it would be interesting to determine whether NFATc1 also interacts with other members of the MyoD family and whether these interactions influence gene expression or fiber type control.
Distinct Roles for NFAT Isoforms in Skeletal Muscle
In the studies here, we show clearly that NFATc1 blocks MyoD activity, whereas NFATc3 does not. We also show that NFATc1 physically associates with MyoD. Previous studies have suggested that NFATc3 also physically associates with MyoD and that this association promotes MyoD activity (Armand et al., 2008; Delling et al., 2000) . In contrast, we did not observe cooperative activation of the myogenin promoter by NFATc3 and MyoD (Figure 1 ), nor did we observe augmentation of MyoD activity in the myotube conversion assay by NFATc3 (data not shown). Together, these observations suggest that the physical interaction of MyoD with NFATc1 versus NFATc3 likely results in distinct coactivator and corepressor interactions by different NFAT family members. Our studies also suggest that NFATc1 may be the primary NFAT isoform downstream of calcineurin responsible for regulating skeletal muscle fiber type because loss-of-function studies for the other nfat genes found no defects in skeletal muscle fiber type (Graef et al., 2001; Horsley et al., 2001; Kegley et al., 2001 ).
Implications for NFATc1 Regulation of MyoD in Sarcopenia and Muscle Atrophy
Slow type I fibers remain relatively constant in size with age, whereas fast type II muscle fiber size diminishes (Porter et al., 1995) . The atrophy that occurs in fast muscle fibers during sarcopenia is believed to play a major role in the pathogenesis of frailty and the functional impairment that occurs with old age or extended bed rest (Evans, 2010) . Basal expression of myogenic C3H10T1/2 cells were cotransfected with MyoD and p300 plus or minus NFATc1, and lysates were analyzed by anti-p300 immunoprecipitation followed by antiMyoD western blot (A), or cells were allowed to differentiate and were analyzed for myotube formation (C-E). bHLH genes increases in proportion to the degree of sarcopenia in senescent muscle (Kim et al., 2005 mice were crossed to female Mef2c-AHF-Cre mice (Rojas et al., 2008) . When crossed from the female, Mef2c-AHF-Cre functions as a universal deleter line, resulting in Cre-dependent recombination in all cells in all offspring (B.L.B., unpublished data). Voluntary exercise assays using 42-day-old male mice were conducted as described previously (Jaehnig et al., 2006) . All experiments using animals were reviewed and approved by the University of California, San Francisco Institutional Animal Care and Use Committee and complied with institutional and federal guidelines.
RNA Extraction, Real-Time qPCR, and ChIP Total RNA was prepared from mouse tissues using the RNeasy Fibrous Tissue Mini Kit (QIAGEN). RNA was treated for 1 hr at 37 C with DNaseI, followed by cDNA synthesis using the Omniscript RT kit (QIAGEN). For chromatin immunoprecipitation (ChIP), soleus muscles of 42-day-old control and nfatc1 SkMKO run mice were frozen, minced, and fixed with 1% formaldehyde in PBS for 10 min at 37 C. ChIP was performed as previously described (Lee et al., 2006) . Immunoprecipitation was performed with rabbit a-acetyl CBP/p300 (no. 4771; Cell Signaling Technology) or control immunoglobulin G (IgG) (ab46540 ChIP grade; Abcam). Immunoprecipitated chromatin was eluted and reverse crosslinked overnight at 65 C. qPCR was performed using the MAXIMA SYBR Green kit (Fermentas) and a 7900HT Fast Real Time PCR System. The SDS 2.4 software package was used to extract raw data. Primer sequences are available on request.
Plasmids and Mutagenesis
Plasmids Mef2c-73k-lacZ (mef2c-lacZ), Mgn184-luciferase, pG 5 E1b-luciferase, pRK5-MyoD, GAL4(DBD)-E12bHLH, E12-VP16, GAL4(DBD)-MyoD, and GAL4(DBD)-MyoD(bHLH) have been described (Black et al., 1998; Dodou et al., 2003; Heidt et al., 2007) . Plasmid Mef2c [-106 ]-73k-lacZ (no NFAT sites) contains nucleotides À106 to +105 relative to the Mef2c skeletal muscle transcriptional start site. Plasmid mrf4-lacZ was generated by cloning a previously described 390 bp region of the mouse mrf4 promoter (Black et al., 1995) into the promoterless vector pAUG-b-gal (Rojas et al., 2008) . Mouse NFATc1, NFATc3, and NFATc4 cDNAs were subcloned into pRK5 to create expression plasmids. A 316 bp fragment encoding the first 101 amino acids of mouse MyoD was cloned into vector PCS2+MT to create the MyoD N-terminal expression plasmid. Truncation and deletion mutants of MyoD and NFATc1 were generated by PCR and confirmed by sequencing; amplicons were digested and subcloned into pRK5-FLAG. The p300 cDNA was obtained from Addgene and subcloned into pRK5 for expression studies.
Cell Culture, Transfections, and Reporter Assays Transfections were performed using Lipofectamine LTX (Invitrogen) with 3 mg plasmid DNA per 35 mm dish. Cells were incubated in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum for 16 hr posttransfection and then were switched to DMEM with 2% horse serum for 5 days for myotube conversion assays or for 36 hr for all other transfection experiments. Cellular extracts were normalized and assayed for b-galactosidase or luciferase activity as previously described (Heidt et al., 2007; Rojas et al., 2008) .
All transfections lacking an expression plasmid contained parental vector DNA such that each transfection had an equivalent amount of plasmid DNA.
Coimmunoprecipitation and Western Blotting
Cells or tissues were washed in 4 C PBS and then lysed and homogenized in either cracking buffer (835 mM sucrose, 1.7% SDS, and 170 mM Tris-HCl [pH 8.8]) or radio immunoprecipitation assay buffer (50 mM Tris [pH 7.4], 150 mM NaCl, 2 mM EDTA, 1% NP-40, and 0.1% SDS) in the presence of a protease inhibitor cocktail (Roche) for tissue culture cells or muscle tissue, respectively. Lysates were incubated at 4 C overnight with primary antibody or isotype control and then for 2 hr with 100 mg Protein G Sepharose beads (Sigma-Aldrich). Samples were then subjected to SDS-PAGE and western blot using standard procedures. The following antibodies were used: rabbit a-MyoD (sc-760; Santa Cruz Biotechnology), mouse anti-myosin fast (MY-32; Sigma-Aldrich; 1:1,000), mouse anti-slow myosin (M8421; Sigma-Aldrich; 1:1,000), mouse a-NFATc1 (clone 7A6; BD PharMingen; 1:1,000), and rabbit a-acetyl CBP/ p300 (no. 4771; CST). For FLAG-and Myc-tagged proteins, mouse a-FLAG (M2; Sigma-Aldrich; 1:1,000) and mouse a-myc (clone 9E10; Sigma-Aldrich; 1:1,000) were used. Mouse anti-tubulin (DSHB; 1:500) was used as a loading control. Horseradish-peroxidase-conjugated anti-mouse (A4416; SigmaAldrich; 1:1,000) was used as the secondary antibody.
Immunohistochemistry, Immunofluorescence, and Metachromatic ATPase Staining Immunohistochemical staining using the Vectastain Elite ABC kit (Vector Laboratories; PK-6102) and immunofluorescence were performed as described (Rojas et al., 2008) . The following antibodies were used: rabbit anti-NFATc1 (sc-13033; Santa Cruz Biotechnology; 1:100), goat anti-MyoD (sc-31942; Santa Cruz Biotechnology; 1:100), mouse anti-slow myosin (M8421; SigmaAldrich; 1:250), and mouse anti-fast myosin (MY-32; Sigma-Aldrich; 1:250). Biotin-conjugated goat anti-rabbit (Molecular Probes; 1:300), Alexa Fluor 594 donkey anti-mouse (Molecular Probes; 1:500), Alexa Fluor 488 donkey anti-rabbit (Molecular Probes; 1:500), Alexa Fluor 594 donkey anti-goat (Molecular Probes; 1:500), and Alexa Fluor 647 chicken anti-mouse (Molecular Probes; 1:500) were used as secondary antibodies. Metachromatic ATPase staining with 0.1% toluidine blue was performed as described (Ogilvie and Feeback, 1990) .
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